Syncom Formulations (India) Ratios

Syncom Formulations (India) Ltd Ratios

The Syncom Formulations (India) Ltd Ratios page provides a complete fundamental analysis of Syncom Formulations (India) Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Syncom Formulations (India) Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Syncom Formulations (India) Ltd (NSE: SYNCOMF, BSE: 524470) is currently trading at ₹13.24, with a market capitalization of ₹12.88B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Syncom Formulations (India) Ltd remains a key stock for fundamental analysis using Syncom Formulations (India) Ltd Ratios.

Syncom Formulations (India) Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Syncom Formulations (India) Ltd P/E ratio currently stands at 31.28, making it one of the most tracked metrics in Syncom Formulations (India) Ltd Ratios.

Historically, the Syncom Formulations (India) Ltd P/E ratio has shown strong fluctuations:

• 2024: 31.28
• 2023: 41.52
• 2022: 27.29
• 2021: 46.91
• 2020: 8.39

The decline in Syncom Formulations (India) Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Syncom Formulations (India) Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 4.52.

Historical P/B trend:

• 2024: 4.52
• 2023: 3.65
• 2022: 2.17
• 2021: 4.13

Syncom Formulations (India) Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Syncom Formulations (India) Ltd P/S ratio currently stands at 3.38, an important part of Syncom Formulations (India) Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 3.38
• 2023: 4.05
• 2022: 2.46
• 2021: 4.26

A stable or declining Syncom Formulations (India) Ltd P/S ratio indicates cautious market sentiment.

Syncom Formulations (India) Ltd Price to Cash Flow Ratio (P/CF)

The Syncom Formulations (India) Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 68.51.

Historical Syncom Formulations (India) Ltd Price to Cash Flow Ratio:

• 2024: 68.51
• 2023: 0
• 2022: 74.05
• 2021: 61.99
• 2020: 0

The rising Syncom Formulations (India) Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Syncom Formulations (India) Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Syncom Formulations (India) Ltd EV currently stands at ₹14.61B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 14.61B
• 2023: 9.92B
• 2022: 5.6B
• 2021: 9.44B

Syncom Formulations (India) Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Syncom Formulations (India) Ltd EV/EBITDA ratio is currently 31.06, a key metric in Syncom Formulations (India) Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 31.06
• 2023: 37.99
• 2022: 30.40
• 2021: 50.50

Stable Syncom Formulations (India) Ltd EV/EBITDA indicates balanced valuation.

Syncom Formulations (India) Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Syncom Formulations (India) Ltd D/E ratio is currently 0.01, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.01
• 2023: 0.25
• 2022: 0.32
• 2021: 0.26

Syncom Formulations (India) Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Syncom Formulations (India) Ltd ROE currently stands at 15.69%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 15.69
• 2023: 9.30
• 2022: 8.39
• 2021: 9.66

Syncom Formulations (India) Ltd maintains stable profitability levels.

Syncom Formulations (India) Ltd Ratios Analysis Summary

The Syncom Formulations (India) Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Syncom Formulations (India) Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Syncom Formulations (India) Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.